|
1.
Kyowa Hakko Kogyo Co., Ltd. Kyowa Hakko Kogyo Co., Ltd. File Format: PDF/Adobe Acrobat - View as HTML Kyowa Hakko Kogyo Co., Ltd. Fiscal 2007 First Half Results. Kyowa Hakko Kogyo Co., Ltd. Fiscal 2007 First Half Results. October 30, 2007 ... 2.
Kyowa Hakko Kirin_Kyowa Hakko News_KYOWA -News Release- Lonza and ... Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ... 3.
Kyowa Hakko Kirin_Kyowa Hakko News_Jun 21 Or Kyowa Hakko's West Coast office, 85 Enterprise, Suite 430, Aliso Viejo, California 92656, TEL -- 949-425-0707. FAX -- 949-425-0708. ... 4.
Kyowa Hakko Kirin_Corporate History A guide to the Kyowa Hakko Kirin business vision, corporate overview, ... the life sciences business field (pharmaceuticals, enzymes and seeds) were made. ... 5.
Kyowa Hakko Kirin_Kyowa Hakko News_Alnylam and Kyowa Hakko Form ... Oct 1, 2008 ... In the U.S., the U.K., and China, they are pushing ahead with the clinical ... The new company "Kyowa Hakko Kirin Co., Ltd." will start ... 6.
Kyowa Hakko Kirin_Kyowa Hakko Kirin Group_Kyowa Hakko Bio Business Outline, Amino acids, nucleic acids and medical supplies raw materials import, export and sales. Web site, New window opens Kyowa Hakko U.S.A. Inc. ... 7.
Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin is a new pharmaceutical company with biotechnology as its ... In addition to pharmaceuticals, the Kyowa Hakko Kirin Group is also ... 8.
Kyowa Hakko Kirin_Kyowa Hakko Kirin Group_Kyowa Hakko Food Specialties Kyowa Hakko Food Specialties, based on fermentation and some technology built by experience of the long term, manufactures and sells savory seasonings and ... 9.
Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin is a new pharmaceutical company with biotechnology as its ... In addition to pharmaceuticals, the Kyowa Hakko Kirin Group is also ... 10.
Kyowa Hakko Kirin_R&D_Antibody Engineering Technology_Enhanced ... The further enhancement of this mechanism is attracting global attention as a next-generation antibody engeneering technology. Such enhancement will bring ... |
